Michael Abramoff
Dr. Michael D. Abramoff, MD, PhD, is a fellowship-trained retina specialist, computer scientist and entrepreneur. He is Founder and CEO of IDx Technologies, Inc., the first company ever to receive FDA clearance for an autonomous AI diagnostic system. In this capacity, as an expert on AI in healthcare, he has been invited to brief the US Congress, the White House, the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC).
In 2010, Dr. Abramoff’s research findings led him to found IDx Technologies Inc. to bring to patients more affordable, more accessible, and higher quality healthcare. IDx is a leading AI diagnostics company on a mission to transform the affordability, quality, and accessibility of healthcare. The company is focused on developing clinically-aligned autonomous AI systems. By enabling diagnostic assessment in primary care settings, IDx aims to increase patient access to high-quality, affordable disease detection. In 2018, IDx became the first company ever to receive FDA clearance for an autonomous AI diagnostic system. The system, called IDx-DR, detects diabetic retinopathy without requiring a physician to interpret the results, and has been implemented widely in primary care clinics all over the US and in Europe.
As a physician-scientists, Dr. Abramoff continues to treat patients with retinal disease and trains medical students, residents, and fellows, as well as engineering graduate students at the University of Iowa. Dr. Abramoff has published over 270 peer reviewed journal papers (h-index 59) on AI, image analysis, and retinal diseases, that have been cited over 28,000 times, as well as many book chapters. He is the inventor on US 17 patents and 5 patent applications on AI, medical imaging and image analysis.
